Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American S...
01 Novembre 2018 - 9:03PM
– Differentiated Syk/JAK Inhibitor Studied
in Patients with Heavily Pre-Treated T-Cell Malignancies
–
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced
that new interim results from the Company’s ongoing Phase 2a study
of cerdulatinib in patients with relapsed/refractory peripheral
T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), will
be presented during an oral session at the 2018 American Society of
Hematology (ASH) Annual Meeting, December 1-4, 2018 in San Diego,
California.
The Company also will present new outcomes-based
research on the burden of hospital readmissions for venous
thromboembolism among patients with cancer during an oral session
on Sunday, December 2, and two investigator-initiated animal
studies highlighting the anticoagulant reversal agent Andexxa
[coagulation Factor Xa (recombinant), inactivated-zhzo] will
be presented in poster sessions.
“As shown at the American Society of Clinical
Oncology and European Hematology Association meetings earlier this
year, cerdulatinib has shown encouraging results across a range of
B- and T-cell malignancies and we look forward to presenting new
data specifically focused on patients with PTCL and CTCL,” said
John Curnutte, M.D., Ph.D., head of research and development for
Portola. “These data also will serve as a basis for further
discussions with regulatory agencies regarding the potential
regulatory path forward for cerdulatinib in certain tumor
subtypes.” Cerdulatinib is an investigational oral, dual Syk/JAK
kinase inhibitor that uniquely inhibits two key cell signaling
pathways that promote cancer cell growth in certain hematologic
malignancies. It is being developed for the treatment of resistant
or relapsed hematologic cancer.
Oral Presentations
- 1001. The Novel Syk/JAK Inhibitor Cerdulatinib
Demonstrates Good Tolerability and Clinical Response in a Phase 2a
Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and
Cutaneous T-Cell LymphomaAbstract:
https://ash.confex.com/ash/2018/webprogram/Paper119944.htmlSession:
624 (Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T
Cell Lymphoma: Chemotherapy and Targeted Approaches)Presenter:
Steven M. Horwitz, M.D., Memorial Sloan-Kettering Cancer
CenterDate: Monday, December 3, 2018 at 7:15 p.m. PST; Room 6F
- 365. Burden of Hospital Readmissions for Venous
Thromboembolism Among Patients with CancerAbstract:
https://ash.confex.com/ash/2018/webprogram/Paper112288.htmlSession:
901 (Health Services Research—Non-Malignant Conditions: Thrombosis
and AnticoagulationHematology Disease Topics &
Pathways)Presenter: Alpesh Amin, M.D., M.B.A., UC IrvineDate:
Sunday, December 2, 2018 at 10:30 a.m. PST; Room 8
Poster Presentations
- 2456. Reversal of Apixaban Anticoagulation with Reduced
Doses of Andexanet Alfa in a Porcine Polytrauma
ModelAbstract:
https://ash.confex.com/ash/2018/webprogram/Paper114426.htmlSession:
321 (Blood Coagulation and Fibrinolytic Factors: Poster II
Hematology Disease Topics & Pathways)Presenter: Oliver Grottke,
M.D., Ph.D., M.P.H., University Hospital RWTH Aachen, GermanyDate:
Sunday, December 2, 2018 from 6:00 – 8:00 p.m. PST; Hall GH
- 3778. Comparison of Second and First Generation of
Andexanet Alfa in a Porcine Polytrauma Model with Apixaban
AnticoagulationAbstract:
https://ash.confex.com/ash/2018/webprogram/Paper114542.htmlSession:
321 (Blood Coagulation and Fibrinolytic Factors: Poster II
Hematology Disease Topics & Pathways)Presenter: Oliver Grottke,
M.D., Ph.D., M.P.H., University Hospital RWTH Aachen, GermanyDate:
Monday, December 3, 2018 from 6:00 – 8:00 p.m. PST; Hall GH
About Portola Pharmaceuticals, Inc.Portola
Pharmaceuticals is a commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic diseases. The Company’s
two FDA-approved medicines are Andexxa® [coagulation factor Xa
(recombinant), inactivated-zhzo], the first and only antidote for
patients treated with rivaroxaban and apixaban when reversal of
anticoagulation is needed due to life-threatening or uncontrolled
bleeding, and Bevyxxa® (betrixaban), the first and only oral,
once-daily Factor Xa inhibitor for the prevention of VTE in adult
patients hospitalized for an acute medical illness. The company
also is advancing cerdulatinib, a Syk/JAK inhibitor for the
treatment of hematologic cancers.
Investor Contact: Cara Miller Portola
Pharmaceuticalsir@portola.com
Media Contact:Patrick RyanPure
Communications pryan@purecommunications.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur